At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 45 target
Drug / intervention
NESS L300 Plus Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Safety and Performance of the NESS L300 Plus System
In Brief
A Phase 3 clinical trial evaluating NESS L300 Plus System for Foot Drop and 2 related conditions. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The study is designed to evaluate the safety and efficacy of using the L300 Plus as a neuroprosthesis device for walking in patients following an UMN injury or disease. The clinical study is proposed to determine the anticipated adverse event rate and treatment outcomes at the conclusion of the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFoot Drop, Thigh Muscles Weakness (Hamstrings or Quadriceps), Upper Motor Neuron Injury or Disease
CountriesIsrael
CollaboratorsBioness Neuromodulation
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedNov 2010
Primary CompletionJan 2011
TodayJul 2026
First PostedNov 10, 2010
Enrollment StartSep 1, 2010
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.6 years ago
Interventions
NESS L300 Plus Systemdevice
The patients will receive the device for daily use of six (6) weeks.